TY  - GEN
AU  - Ewa Marcinkowska (Ed)
AU  - Geoffrey Brown (Ed)
TI  - The Biology and Treatment of Myeloid Leukaemias
SN  - 9783038427964
PY  - 2018///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - mouse models
KW  - myelopoiesis
KW  - leukaemia stem cells
KW  - gene aberrations
KW  - new therapy strategies
KW  - disease classification and diagnosis
KW  - disease monitoring
KW  - differentiation therapy
KW  - cellular signaling and other molecular events
KW  - acute myeloid leukaemias
N1  - Open Access
N2  - There has been an observed decrease in the global mortality from cancer, mostly atributable to improved, particularly early, detection and prevention. For many carcinomas and leukaemias in adults, once the disease has reached a certain stage there are no therapies that are able to erradicate the cancer cells and cure patients. There has been progress in the treatment of acute myeloid leukaemia (AML) and remissions are achievable; however, the presence of chemoresistent blast cells leads to most patients relapsing, and relapse is difficult to treat and thus patients die due to their disease. Targeting these resistent cells and the leukaemia stem cells, which sustain the leukaemia, is crucial for an effective therapy for AML. Moreover, an increasing number of diverse mutations have been described in AML cells that disrupt the ability of these cells to undergo differentiation. The use of pro-differentiating agents to drive the blast cells to mature, and subsequently undergo apoptosis, provides another approach to therapy. Differentiation therapy, using all-trans retinoic acid (ATRA), an inducer of granulocyte differentiation, has been highly successful in the case of acute promyeloicytic leukaemia, a sub-type of AML, turning this disease into a curable malignancy
UR  - http://www.mdpi.com/books/pdfview/book/586
UR  - https://directory.doabooks.org/handle/20.500.12854/42238
ER  -